Lung Therapeutics is a therapeutics for lung injury and disease company founded in 2013 by Andrew Mazar, Steven Idell and Sreerama Shetty.
On September 30, 2015 Lung Therapeutics completed their series A funding with $2.6 million in funding from UT Horizon Fund.
On June 6, 2017 Lung Therapeutics completed their series B funding round with $14.3 million in funding from Bios Partners (lead investor) and UT Horizon Fund.